Differential likelihood of NSTEMI vs STEMI in patients with sleep apnea.

Int J Cardiol

Department of Cardiovascular Diseases and International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic; Department of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN, United States; Department of Cardiovascular Diseases, Heart Hospital of Hamad Medical Corporation, Doha, Qatar; Center for Cardiovascular and Transplant Surgery Brno, Brno, Czech Republic. Electronic address:

Published: December 2017

Background: Sleep apnea (SA) is associated with intermittent hypoxemia that may lead to ischemic preconditioning in the myocardium. This potential cardioprotective effect of SA may play a role in the development of non-ST-elevation myocardial infarction (NSTEMI) versus ST-elevation myocardial infarction (STEMI) during acute ischemia. However, there is limited evidence about the relative prevalence of NSTEMI versus STEMI in SA patients. We therefore prospectively investigated the prevalence of these two types of MI in patients with SA.

Methods: We prospectively studied 782 consecutive patients admitted with the diagnosis of acute MI (both NSTEMI and STEMI). All subjects underwent sleep evaluations using a portable diagnostic device after at least 48h post-admission, provided they were in stable condition. Six hundred and seven out of 782 patients had technically adequate sleep studies, and therefore were included in the final analysis.

Results: SA was present in 65.7% (n=399) and NSTEMI in 30% (n=182) of patients. Increasing severity of SA was associated with increasing likelihood of NSTEMI, and with decreasing likelihood of STEMI (p<0.001). Relative frequency of NSTEMI in the moderate to severe SA group (AHI≥15events/h) was 40.6% versus 29.9% for STEMI (p=0.01).

Conclusion: The prevalence of NSTEMI increases with increasing severity of SA. This finding may suggest a cardioprotective role of SA, which may attenuate the development of STEMI, perhaps through ischemic preconditioning.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2017.06.034DOI Listing

Publication Analysis

Top Keywords

likelihood nstemi
8
nstemi stemi
8
stemi patients
8
sleep apnea
8
myocardial infarction
8
nstemi versus
8
nstemi
6
patients
6
stemi
5
differential likelihood
4

Similar Publications

Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality worldwide. Risk factors of mortality in patients with AMI have been widely investigated, identifying older age and heart failure as common contributors. This study aimed to determine risk factors and explore predictors associated with higher mortality among patients with AMI.

View Article and Find Full Text PDF

Purpose Of Review: This review assesses the outcomes of coronary interventions in patients with liver cirrhosis and coronary artery disease (CAD), focusing on the clinical challenges posed by cirrhosis-related hemodynamic and coagulopathic changes. It highlights essential considerations for managing these patients, who have an increased risk of adverse events during coronary procedures.

Recent Findings: Recent studies have shown that patients with liver cirrhosis undergoing PCI experience significantly higher mortality rates compared to non-cirrhotic patients, particularly in the context of STEMI and NSTEMI.

View Article and Find Full Text PDF

Acute coronary syndrome (ACS) is one of the most common leading global causes of mortality, encompassing ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Percutaneous coronary intervention (PCI) has become a pivotal therapeutic approach for ACS, underscoring the importance of anticoagulation strategies. Among the commonly employed anticoagulants in PCI, heparin and bivalirudin take precedence, with heparin serving as the archetypal choice.

View Article and Find Full Text PDF

Mortality prediction of inpatients with NSTEMI in a premier hospital in China based on stacking model.

PLoS One

December 2024

Department of Cardiology, The People's Hospital of China Medical University, The People's Hospital of Liaoning Province, Shenyang, China.

Background: Acute myocardial infarction (AMI) remains a leading cause of hospitalization and death in China. Accurate mortality prediction of inpatient is crucial for clinical decision-making of non-ST-segment elevation myocardial infarction (NSTEMI) patients.

Methods: In this study, a total of 3061 patients between January 1, 2017 and December 31, 2022 diagnosed with NSTEMI were enrolled in this study.

View Article and Find Full Text PDF

Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.

BMC Cardiovasc Disord

December 2024

State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater Command, 83 Wenhua Road, Shenyang, Liaoning, 110016, China.

Introduction: In clinical practice, the dose of bivalirudin may not be fully applicable to the Chinese population. Therefore, this study aimed to explore the efficacy and safety of a reduced dose (80% of the recommended dose) of bivalirudin without post-procedure infusion for 3-4 h in patients with acute coronary syndrome (ACS) undergoing elective percutaneous coronary intervention (PCI).

Methods: This was a single-center, retrospective study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!